Bonlutin

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

natural fish oil, Quantity: 600 mg (Equivalent: eicosapentaenoic acid, Qty 90 mg; Equivalent: docosahexaenoic acid, Qty 60 mg); glucosamine sulfate potassium chloride, Quantity: 500 mg (Equivalent: glucosamine, Qty 296 mg; Equivalent: potassium chloride, Qty 123 mg); shark sodium chondroitin sulfate, Quantity: 12.33 mg (Equivalent: chondroitin sulfate, Qty 10 mg)

Disponible depuis:

Pharmametics Products A Division of Max Biocare Pty Ltd

forme pharmaceutique:

Capsule, soft

Composition:

Excipient Ingredients: Gelatin; iron oxide red; d-alpha-tocopherol; hydrogenated vegetable oil; iron oxide black; lecithin; yellow beeswax; purified water; Soya Oil; glycerol; titanium dioxide; propylene glycol; ethyl acetate; ethanol; isopropyl alcohol; strong ammonia solution; polyvinyl acetate phthalate; macrogol 400

Mode d'administration:

Oral

indications thérapeutiques:

Antioxidant/Reduce free radicals formed in the body ; Anti-inflammatory/relieve inflammation ; Decrease/reduce/relieve mild joint aches and pains ; Decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis ; Helps maintain/supports healthy joint cartilage growth/development/production ; Helps enhance/promote healthy joint function ; Helps enhance/promote joint health ; Maintain/support joint health ; Decrease/reduce/relieve mild joint inflammation/swelling ; Maintain/support joint mobility/flexibility ; Decrease/reduce/relieve mild joint pain/soreness ; Decrease/reduce/relieve mild joint stiffness

Descriptif du produit:

Visual Identification: ;

Statut de autorisation:

Listed

Date de l'autorisation:

2019-08-05